Gland Pharma Uploads Q3 FY26 Earnings Call Recording to Website
Gland Pharma has uploaded the audio recording of its earnings call for Q3 FY26, which took place on January 28, 2026. The recording is available on the company's website.
This is a routine disclosure of an earnings call recording, which is standard practice. It does not introduce new material information that would significantly impact the company's stock or operations.
The announcement is a routine update regarding the availability of an earnings call recording and does not contain new financial information or forward-looking statements that would indicate a positive or negative sentiment.
Gland Pharma Limited has uploaded the audio recording of its earnings call for the quarter and nine months ended December 31, 2025. The call was held on January 28, 2026, at 18:30 Hrs. (IST).
This disclosure follows earlier communications dated January 09, 2026, and is made pursuant to Regulations 30 and 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The weblink to access the audio recording is https://glandpharma.com/images/Q3_FY26.mp3.
This information is for the record and information of the stakeholders.
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.